We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+1.34%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$42.2B
AUM Growth
-$1.23B
(-2.8%)
Cap. Flow
-$952M
Cap. Flow
% of AUM
-2.26%
Top 10 Holdings %
Top 10 Hldgs %
14.57%
Holding
2,171
New
150
Increased
772
Reduced
960
Closed
152
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$156M |
| 2 |
Prologis
PLD
|
+$150M |
| 3 |
Chevron
CVX
|
+$109M |
| 4 |
Qualcomm
QCOM
|
+$101M |
| 5 |
Paycom
PAYC
|
+$90.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$230M |
| 2 |
Kimberly-Clark
KMB
|
+$160M |
| 3 |
Stanley Black & Decker
SWK
|
+$130M |
| 4 |
Paychex
PAYX
|
+$113M |
| 5 |
Dominion Energy
D
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.81% |
| 2 | Healthcare | 17.11% |
| 3 | Financials | 12.73% |
| 4 | Industrials | 9.87% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1476
McCormick & Company Non-Voting
MKC
$13.5B
| $197K | ﹤0.01% |
2,771
+1
| +0% | +$73 |
|
1477
Ametek
AME
$53.2B
| $196K | ﹤0.01% |
1,177
+95
| +9% | +$16.4K |
|
1478
TE Connectivity
TEL
$58.5B
| $196K | ﹤0.01% |
1,302
-50
| -4% | -$7.33K |
|
1479
Materion
MTRN
$5.17B
| $196K | ﹤0.01% |
1,809
-4
| -0.2% | -$460 |
|
|
BCOV
1480
DELISTED
Brightcove, Inc.
BCOV
| $195K | ﹤0.01% |
82,170
-34,729
| -30% | -$68.2K |
|
1481
Atour Lifestyle Holdings
ATAT
$4.36B
| – | – |
0
| – | – |
|
|
HES
1482
DELISTED
Hess
HES
| $193K | ﹤0.01% |
1,310
-232,362
| -99% | -$35.6M |
|
|
PCH
1483
DELISTED
PotlatchDeltic
PCH
| $193K | ﹤0.01% |
4,890
-651
| -12% | -$27.6K |
|
1484
CMS Energy
CMS
$20.7B
| $193K | ﹤0.01% |
3,234
+2,162
| +202% | +$131K |
|
1485
Sociedad Química y Minera de Chile
SQM
$19.6B
| $192K | ﹤0.01% |
4,716
| – | – |
|
1486
Neogen
NEOG
$2.74B
| $192K | ﹤0.01% |
12,282
-21
| -0.2% | -$292 |
|
1487
MasterCraft Boat Holdings
MCFT
$466M
| $190K | ﹤0.01% |
10,072
| – | – |
|
1488
Monster Beverage
MNST
$87.3B
| $190K | ﹤0.01% |
7,590
-7,632
| -50% | -$202K |
|
1489
Tyson Foods
TSN
$18.3B
| $188K | ﹤0.01% |
3,283
+2,265
| +222% | +$132K |
|
1490
Arrowhead Research
ARWR
$9.29B
| $187K | ﹤0.01% |
7,201
-7,537
| -51% | -$185K |
|
1491
Mirum Pharmaceuticals
MIRM
$6.32B
| $185K | ﹤0.01% |
5,400
-3,600
| -40% | -$94.4K |
|
1492
Royalty Pharma
RPRX
$26B
| $185K | ﹤0.01% |
7,000
-2,000
| -22% | -$55.4K |
|
1493
Sotera Health
SHC
$5.52B
| $184K | ﹤0.01% |
15,522
-250
| -2% | -$2.85K |
|
1494
Texas Capital Bancshares
TCBI
$4.14B
| $182K | ﹤0.01% |
2,980
-219
| -7% | -$12.9K |
|
|
CCRN
1495
DELISTED
Cross Country Healthcare
CCRN
| $180K | ﹤0.01% |
12,996
-6,779
| -34% | -$107K |
|
1496
Fastenal
FAST
$56.3B
| $180K | ﹤0.01% |
5,722
-17,350
| -75% | -$585K |
|
1497
Crane NXT
CXT
$2.72B
| $179K | ﹤0.01% |
2,922
-1,929
| -40% | -$118K |
|
1498
Quest Diagnostics
DGX
$27.3B
| $179K | ﹤0.01% |
1,309
+768
| +142% | +$105K |
|
1499
Gen Digital
GEN
$18.3B
| $179K | ﹤0.01% |
7,167
+5,093
| +246% | +$117K |
|
|
ACH
1500
Accendra Health
ACH
$82.3M
| $176K | ﹤0.01% |
13,073
-154,918
| -92% | -$3.17M |
|
Similar funds
Federated Hermes's Q2 2024 Portfolio in Review
As of Q2 2024, Federated Hermes held 2,171 positions worth $42.2B, down 2.8% from $43.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes's Q2 2024 filing shows 150 new, 772 increased, 960 reduced and 152 closed positions. Its largest new stake was Loar Holdings: 729,296 shares worth $39M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $230M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Federated Hermes's largest Q2 2024 buy was Loar Holdings: 729,296 shares worth $39M.
- Federated Hermes added most to Bristol-Myers Squibb in Q2 2024, an estimated $156M increase.
- Federated Hermes's biggest Q2 2024 reduction was Kimberly-Clark, cutting an estimated $160M.
- Federated Hermes fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $230M.
- Federated Hermes's ten largest holdings make up 15% of its $42.2B portfolio in Q2 2024.
- Federated Hermes opened 150 new positions and closed 152 in Q2 2024.
- Federated Hermes's portfolio value fell 2.8% quarter-over-quarter to $42.2B.
Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.